Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646611 | 0.89 | SCN10A (0.46) | MAPTTP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6646504 | 0.83 | EIF2AK3 (0.42) | MAPTTP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6644233 | 0.83 | MAPT (0.55) | MAPTTP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6647476 | 0.80 | SCN10A (0.46) | RAB9ASMN1; SMN2NPC1SCN10ALMNA | |
| SCHEMBL6649737 | 0.78 | SCN10A (0.51) | MAPTTP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6649216 | 0.78 | CASP3 (0.44) | MAPTTP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6645438 | 0.77 | SCN10A (0.42) | MAPTTP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6828987 | 0.76 | SCN10A (0.52) | SCN10AALDH1A1TSHRKDM4EHSD17B10 | |
| SCHEMBL6645197 | 0.76 | SCN10A (0.53) | MAPTTP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6648859 | 0.76 | SCN10A (0.41) | MAPTTP53RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | MAPT 4101/4885TP53 4513/4885RAB9A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.